Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DC in multiple myeloma immunotherapy.

C J Turtle1, R D Brown, D E Joshua

  • 1Dendritic Cell Laboratory, Mater Medical Research Institute, Raymond Terrace, South Brisbane, Queensland, Australia.

Cytotherapy
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.

Nature communications·2024
Same author

CD10-(CALLA)-Positive Lymphocytes in Myeloma: Evidence that they are a Malignant Precursor Population and are of Germinal Centre Origin.

Leukemia & lymphoma·2016
Same author

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Clinical pharmacology and therapeutics·2016
Same author

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Leukemia·2015
Same author

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Leukemia·2015
Same author

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Blood cancer journal·2013
Same journal

CAR T cells: The next frontier.

Cytotherapy·2026
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
See all related articles

Dendritic cell (DC) immunotherapy shows promise for multiple myeloma (MM) patients, as in vitro manipulation can restore abnormal DC function, potentially improving outcomes in this challenging cancer.

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • Multiple myeloma (MM) therapy is often unsatisfactory, with most patients experiencing disease relapse.
  • Dendritic cells (DCs), crucial for adaptive immunity, play a role in anti-cancer responses.
  • DC function is frequently impaired in MM patients, necessitating therapeutic strategies.

Purpose of the Study:

  • To review the immunological basis for anti-MM responses.
  • To discuss DC dysfunction in MM.
  • To explore the potential of dendritic cell immunotherapy for multiple myeloma.

Main Methods:

  • Literature review of anti-MM immune response research.
  • Analysis of dendritic cell abnormalities in MM patients.
  • Examination of clinical trial data for DC immunotherapy in MM.

Related Experiment Videos

Main Results:

  • Evidence suggests an anti-MM immune response exists.
  • In vitro manipulation may restore aberrant DC function in MM.
  • Clinical trials of DC immunotherapy are being conducted for MM.

Conclusions:

  • Dendritic cell immunotherapy is a developing strategy for multiple myeloma.
  • Restoring DC function offers a potential therapeutic avenue.
  • Further research and clinical trials are essential for MM treatment.